T-DM1 for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
Squires H, Simpson E, Harvey R, Stevens J, Buckley Woods H, Stevenson M
Record ID 32014000166
English
Authors' objectives:
To appraise the clinical and cost effectiveness of trastuzumab emtansine within its licensed indication for the treatment of unresectable locally advanced or metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane.
Details
Project Status:
Completed
URL for project:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/126501/#/
Year Published:
2014
URL for published report:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/126501/#/
Requestor:
NIHR Health Technology Assessment programme
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England, United Kingdom
MeSH Terms
- Trastuzumab
- Breast Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Maytansine
- Ado-Trastuzumab Emtansine
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.